Rafael Holdings says Trappsol Cyclo Phase 3 study in Niemann-Pick Type C results
Rafael Holdings reported topline results from a pivotal Phase 3 Transportnpc study of Trappsol Cyclo in Niemann-Pick disease Type C, saying it was well-tolerated but did not achieve statistical significance on the primary endpoint at Week 96. The company said it is on track to submit an NDA in Q4 2026.
Sept 30 (Reuters) — Rafael Holdings Inc: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-pick Disease Type C (Npc) Rafael - Company On Track To Submit Nda For Trappsol Cyclo In Q4 2026 Rafael - Trappsol Cyclo Did Not Achieve Statistical Significance On Primary Endpoint At Week 96 Rafael - Trappsol Cyclo Demonstrates Well-tolerated Safety Profile With No New Safety Signals Source text:... com;;)